Quantitative CT texture analysis in predicting PD-L1 expression in locally advanced or metastatic NSCLC patients.
Chest CT
Lung cancer
PD-L1 expression
Texture analysis
Journal
La Radiologia medica
ISSN: 1826-6983
Titre abrégé: Radiol Med
Pays: Italy
ID NLM: 0177625
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
09
11
2020
accepted:
06
07
2021
pubmed:
11
8
2021
medline:
19
11
2021
entrez:
10
8
2021
Statut:
ppublish
Résumé
The assessment of Programmed death-ligand 1 (PD-L1) expression has become a game changer in the treatment of patients with advanced non-small cell lung cancer (NSCLC). We aimed to investigate the ability of Radiomics applied to computed tomography (CT) in predicting PD-L1 expression in patients with advanced NSCLC. By applying texture analysis, we retrospectively analyzed 72 patients with advanced NSCLC. The datasets were randomly split into a training cohort (2/3) and a validation cohort (1/3). Forty radiomic features were extracted by manually drawing tumor volumes of interest (VOIs) on baseline contrast-enhanced CT. After selecting features on the training cohort, two predictive models were created using binary logistic regression, one for PD-L1 values ≥ 50% and the other for values between 1 and 49%. The two models were analyzed with ROC curves and tested in the validation cohort. The Radiomic Score (Rad-Score) for PD-L1 values ≥ 50%, which consisted of Skewness and Low Gray-Level Zone Emphasis (GLZLM_LGZE), presented a cut-off value of - 0.745 with an area under the curve (AUC) of 0.811 and 0.789 in the training and validation cohort, respectively. The Rad-Score for PD-L1 values between 1 and 49% consisted of Sphericity, Skewness, Conv_Q3 and Gray Level Non-Uniformity (GLZLM_GLNU), showing a cut-off value of 0.111 with AUC of 0.763 and 0.806 in the two population, respectively. Rad-Scores obtained from CT texture analysis could be useful for predicting PD-L1 expression and guiding the therapeutic choice in patients with advanced NSCLC.
Identifiants
pubmed: 34373989
doi: 10.1007/s11547-021-01399-9
pii: 10.1007/s11547-021-01399-9
pmc: PMC8558266
doi:
Substances chimiques
B7-H1 Antigen
0
CD274 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1425-1433Informations de copyright
© 2021. The Author(s).
Références
Cancer Imaging. 2013 Mar 26;13:140-9
pubmed: 23545171
J Thorac Oncol. 2016 Mar;11(3):300-11
pubmed: 26723244
Clin Radiol. 2017 Jun;72(6):443-450
pubmed: 28258739
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Eur J Radiol. 2019 Nov;120:108609
pubmed: 31606714
Sci Rep. 2016 Jan 29;6:20090
pubmed: 26822379
Acad Radiol. 2020 Feb;27(2):171-179
pubmed: 31147234
Radiographics. 2017 Sep-Oct;37(5):1483-1503
pubmed: 28898189
Clin Lung Cancer. 2015 Sep;16(5):385-90
pubmed: 25937270
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
JAMA Oncol. 2016 Jan;2(1):46-54
pubmed: 26562159
J Thorac Oncol. 2017 Mar;12(3):458-466
pubmed: 27815126
Thorac Cancer. 2020 Apr;11(4):993-1004
pubmed: 32043309
Eur J Nucl Med Mol Imaging. 2020 May;47(5):1137-1146
pubmed: 31728587
Radiology. 2020 May;295(2):328-338
pubmed: 32154773
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Eur Radiol. 2018 Jul;28(7):2772-2778
pubmed: 29450713
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
J Xray Sci Technol. 2020;28(3):449-459
pubmed: 32176676
Cancer Res. 2018 Aug 15;78(16):4786-4789
pubmed: 29959149
J Immunother Cancer. 2018 Jul 17;6(1):75
pubmed: 30012210
Lancet Oncol. 2016 Nov;17(11):1497-1508
pubmed: 27745820
Ann Oncol. 2016 Jan;27(1):147-53
pubmed: 26483045
Clin Lung Cancer. 2016 Sep;17(5):441-448.e6
pubmed: 27017476
AJR Am J Roentgenol. 2015 Nov;205(5):1016-25
pubmed: 26496549
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Ann Oncol. 2019 Jun 1;30(6):998-1004
pubmed: 30895304